MeSH tree: C15.604.515.569.480
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James), may offer a new treatment option ...
Nov 6, 2023
0
84
A surprising mechanism that makes some cancers treatment-resistant has been discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators. The mechanism, which involves the shuttling of messenger RNAs (mRNAs) ...
Nov 2, 2023
0
47
For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study published online Oct. 18 in ...
Oct 30, 2023
0
64
Northwestern Medicine investigators have discovered how the protein PD-1 controls essential metabolic processes in tumor cells to promote cancer growth in T-cell non-Hodgkin lymphomas (T-NHLs), according to a study published ...
Sep 21, 2023
0
41
Cancer patients appeared to benefit from natural killer cells obtained from donors in an experimental method of treating cancer that involved an aggressive army of immune system fighters endowed with the ability to home in ...
Some patients with aggressive lymphomas face a rare but clinically challenging prognosis when their cancer spreads to the central nervous system (CNS) or relapses there.
Sep 14, 2023
0
36
Researchers from Karolinska Institutet found a high number of the so-called natural killer cells, an important anti-lymphoma cell, in samples from patients with cutaneous lymphoma. However, the cells were immature and less ...
Aug 30, 2023
0
41
The Air Force has detected unsafe levels of a likely carcinogen at underground launch control centers at a Montana nuclear missile base where a striking number of men and women have reported cancer diagnoses.
Aug 8, 2023
0
38
Anaplastic large cell lymphoma, a form of non-Hodgkin lymphoma, is the most common aggressive lymphoma in children. Chemotherapy and radiation fail to cure about 30% of cases. When tumors are driven by the oncogene ALK—which ...
Aug 3, 2023
0
38
Preliminary results of a first-in-human study show manageable toxicity and preliminary antitumor activity of a potential second generation epigenetic therapy for advanced solid tumors
Jul 26, 2023
0
32
